Highly sensitive and reliable plasmonic nanoparticle-based digital cytometry for quantification of MUC16 binding on the surface of leukocytes (Conference Presentation)

We recently developed a digital cytometric assay using plasmonic nanoparticles to quantify the bound ovarian cancer marker (CA125) on single cells. We demonstrate the quantification capability of our novel digital cytometry method by discriminating the different MUC16 binding levels on the PBMCs between healthy donors and EOC patients. Furthermore, we tracked the amount of surface-bound MUC16 on the EOC patient’s PBMCs over 17 months with 1-month time intervals. Initial data from our cytometric technique shows it to be a quantitative tool that can provide new information connecting leukocyte-bound MUC16 to the time course of ovarian cancer.